Latest Medivation Inc (MDVN) Headlines
Medivation Falls 3.83% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Mar 06, 4:47PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $66.53 to a high of $70.95. Yesterday, the shares fell 3.8%, which took the trading range below the 3-day low of $70.05 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Is Medivation Inc's Recent Pullback an Entry Opportunity?
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
Medivation reported fourth quarter 2013 earnings after the bell on February 27 that beat estimates on both the top and bottom lines. Fourth quarter revenue grew 163% on year to $96.61 million, beating estimates by almost $24 million. While the...
Investors Are in Love With Dendreon Corporation
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 03, 6:58PM CST
Dendreon ended up 15% today. I have no idea why. There didn't seem to be anything in today's press releases nor on the conference call that justified that kind of move. Let's take a few quotes that John Johnson, Dendreon's chairman, president,...
Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...
Why Dendreon Corporation Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 11:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Dendreon , a biopharmaceutical company...
Why Clean Energy Fuels, Medivation, and NII Holdings Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Feb 28, 7:01PM CST
Stocks generally finished February on a strong note and, even though the market finished off its highs of the day, the S&P 500 again hit new all-time record highs and lifted most individual stocks along with it. But bad news still hit a few...
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Uptrend Call Working As Medivation Stock Rises 22.8% (MDVN)
Comtex SmarTrend(R) - Fri Feb 28, 4:46PM CST
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on October 23rd, 2013 at $58.57. In approximately 4 months, Medivation has returned 22.78% as of today's recent price of $71.91.
Best Buy and Deckers are big market movers
AP - Fri Feb 28, 4:45PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
Look for Shares of Medivation to Potentially Rebound after Yesterday's 14.92% Sell Off
Comtex SmarTrend(R) - Fri Feb 28, 4:18PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $70.87 to a high of $75.98. Yesterday, the shares fell 14.9%, which took the trading range below the 3-day low of $84.25 on volume of 8.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Medivation (MDVN) Is Down Today
at The Street - Fri Feb 28, 12:31PM CST
Medivation (MDVN) falls after the biopharmaceutical company forecasts guidance that came up well short of analysts' expectations.
Why Medivation, Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:08PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Medivation , a biopharmaceutical company...
Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.
Ahead of the Bell: Medivation shares sink
By The Associated Press - AP - Fri Feb 28, 8:25AM CST
Medivation Inc. tumbled in premarket trading Friday, a day after the drugmaker forecast 2014 revenue from its prostate cancer treatment Xtandi that fell short of analyst expectations.
Today's Top Biotech Stories: Ampio Pharmaceuticals, Auxilium Pharmaceuticals, Bayer, and Medivation
George Budwell, The Motley Fool - Motley Fool - Fri Feb 28, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Downgrade Alert for Medivation (MDVN)
Comtex SmarTrend(R) - Fri Feb 28, 6:58AM CST
Medivation (NASDAQ:MDVN) was downgraded from Market Perform to Underperform at Cowen and Company today. The stock closed yesterday at $84.52 on volume of 1.4 million shares, below average daily volume of 1.6 million. Medivation Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process.
Medivation Falls 3.83% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Mar 06, 4:47PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $66.53 to a high of $70.95. Yesterday, the shares fell 3.8%, which took the trading range below the 3-day low of $70.05 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Is Medivation Inc's Recent Pullback an Entry Opportunity?
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
Medivation reported fourth quarter 2013 earnings after the bell on February 27 that beat estimates on both the top and bottom lines. Fourth quarter revenue grew 163% on year to $96.61 million, beating estimates by almost $24 million. While the...
Investors Are in Love With Dendreon Corporation
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 03, 6:58PM CST
Dendreon ended up 15% today. I have no idea why. There didn't seem to be anything in today's press releases nor on the conference call that justified that kind of move. Let's take a few quotes that John Johnson, Dendreon's chairman, president,...
Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...
Why Dendreon Corporation Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 11:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Dendreon , a biopharmaceutical company...
Why Clean Energy Fuels, Medivation, and NII Holdings Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Feb 28, 7:01PM CST
Stocks generally finished February on a strong note and, even though the market finished off its highs of the day, the S&P 500 again hit new all-time record highs and lifted most individual stocks along with it. But bad news still hit a few...
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Uptrend Call Working As Medivation Stock Rises 22.8% (MDVN)
Comtex SmarTrend(R) - Fri Feb 28, 4:46PM CST
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on October 23rd, 2013 at $58.57. In approximately 4 months, Medivation has returned 22.78% as of today's recent price of $71.91.
Best Buy and Deckers are big market movers
AP - Fri Feb 28, 4:45PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
Look for Shares of Medivation to Potentially Rebound after Yesterday's 14.92% Sell Off
Comtex SmarTrend(R) - Fri Feb 28, 4:18PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $70.87 to a high of $75.98. Yesterday, the shares fell 14.9%, which took the trading range below the 3-day low of $84.25 on volume of 8.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Medivation (MDVN) Is Down Today
at The Street - Fri Feb 28, 12:31PM CST
Medivation (MDVN) falls after the biopharmaceutical company forecasts guidance that came up well short of analysts' expectations.
Why Medivation, Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:08PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Medivation , a biopharmaceutical company...
Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.
Ahead of the Bell: Medivation shares sink
By The Associated Press - AP - Fri Feb 28, 8:25AM CST
Medivation Inc. tumbled in premarket trading Friday, a day after the drugmaker forecast 2014 revenue from its prostate cancer treatment Xtandi that fell short of analyst expectations.
Today's Top Biotech Stories: Ampio Pharmaceuticals, Auxilium Pharmaceuticals, Bayer, and Medivation
George Budwell, The Motley Fool - Motley Fool - Fri Feb 28, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Downgrade Alert for Medivation (MDVN)
Comtex SmarTrend(R) - Fri Feb 28, 6:58AM CST
Medivation (NASDAQ:MDVN) was downgraded from Market Perform to Underperform at Cowen and Company today. The stock closed yesterday at $84.52 on volume of 1.4 million shares, below average daily volume of 1.6 million. Medivation Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process.
